[
  {
    "ts": null,
    "headline": "AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate",
    "summary": "AstraZeneca Plc (NASDAQ:AZN) on Thursday reported high-level results from the PREVAIL Phase 3 trial evaluating the safety and efficacy of gefurulimab in adults with generalized myasthenia gravis (gMG). The trial enrolled 260 patients. MG is a chronic autoimmune disorder that causes muscle weakness and fatigue. The disease is characterized by antibodies against the acetylcholine receptor, a protein found on the surface of nerve cells that plays a key role in muscle contraction. In adults with ant",
    "url": "https://finnhub.io/api/news?id=3517e509b2206d2e92358226a89c67b92774ea23c8c87e3935af1edabdaef0c8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753376923,
      "headline": "AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate",
      "id": 136082847,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "AstraZeneca Plc (NASDAQ:AZN) on Thursday reported high-level results from the PREVAIL Phase 3 trial evaluating the safety and efficacy of gefurulimab in adults with generalized myasthenia gravis (gMG). The trial enrolled 260 patients. MG is a chronic autoimmune disorder that causes muscle weakness and fatigue. The disease is characterized by antibodies against the acetylcholine receptor, a protein found on the surface of nerve cells that plays a key role in muscle contraction. In adults with ant",
      "url": "https://finnhub.io/api/news?id=3517e509b2206d2e92358226a89c67b92774ea23c8c87e3935af1edabdaef0c8"
    }
  },
  {
    "ts": null,
    "headline": "Why Johnson & Johnson (JNJ) is a Top Momentum Stock for the Long-Term",
    "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
    "url": "https://finnhub.io/api/news?id=fa5cbdac47356c7f9027098e504789c3fa65f66d00a95158bd197db897fb3dd2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753365001,
      "headline": "Why Johnson & Johnson (JNJ) is a Top Momentum Stock for the Long-Term",
      "id": 136084818,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
      "url": "https://finnhub.io/api/news?id=fa5cbdac47356c7f9027098e504789c3fa65f66d00a95158bd197db897fb3dd2"
    }
  },
  {
    "ts": null,
    "headline": "J&J Innovative Medicine Unit Shines Again in Q2: Will This Continue?",
    "summary": "JNJ's Innovative Medicine unit posts solid Q2 growth despite Stelara's LOE, powered by Darzalex, Tremfya, Erleada and new drugs.",
    "url": "https://finnhub.io/api/news?id=b0c003928b0c797247e577d10b0d8ddb4ff152a4becfbdf922189047918cab24",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753363380,
      "headline": "J&J Innovative Medicine Unit Shines Again in Q2: Will This Continue?",
      "id": 136084819,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "JNJ's Innovative Medicine unit posts solid Q2 growth despite Stelara's LOE, powered by Darzalex, Tremfya, Erleada and new drugs.",
      "url": "https://finnhub.io/api/news?id=b0c003928b0c797247e577d10b0d8ddb4ff152a4becfbdf922189047918cab24"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson showcases latest advancements in Alzheimer's research at AAIC 2025",
    "summary": "Johnson & Johnson (NYSE: JNJ) today announced promising new data from its Alzheimer's disease (AD) research program will be presented at the Alzheimer's Association International Conference (AAIC), taking place July 27–31 in Toronto, Canada. Across 12 abstracts, the Company will share insight into how tau impacts brain function in early AD and reinforce the predictive strength of plasma biomarker pTau217 for tracking cognitive decline in at-risk individuals. The Company will also introduce findi",
    "url": "https://finnhub.io/api/news?id=f87356dbcfa45a2295bb862c1442adc3292e8c9b4e213162cec9f8794e03998c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753358400,
      "headline": "Johnson & Johnson showcases latest advancements in Alzheimer's research at AAIC 2025",
      "id": 136066250,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced promising new data from its Alzheimer's disease (AD) research program will be presented at the Alzheimer's Association International Conference (AAIC), taking place July 27–31 in Toronto, Canada. Across 12 abstracts, the Company will share insight into how tau impacts brain function in early AD and reinforce the predictive strength of plasma biomarker pTau217 for tracking cognitive decline in at-risk individuals. The Company will also introduce findi",
      "url": "https://finnhub.io/api/news?id=f87356dbcfa45a2295bb862c1442adc3292e8c9b4e213162cec9f8794e03998c"
    }
  },
  {
    "ts": null,
    "headline": "Low IV Alert: Stocks that Could be Ready to Pop",
    "summary": "Market volatility has dropped since the April correction, but with plenty of items on the news front, we could see a volatility spike at any point.",
    "url": "https://finnhub.io/api/news?id=d44991cee97fb85efba395dcf43e3cd3bd07b8610ecae05636e1e45e2801ce22",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753354802,
      "headline": "Low IV Alert: Stocks that Could be Ready to Pop",
      "id": 136066033,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Market volatility has dropped since the April correction, but with plenty of items on the news front, we could see a volatility spike at any point.",
      "url": "https://finnhub.io/api/news?id=d44991cee97fb85efba395dcf43e3cd3bd07b8610ecae05636e1e45e2801ce22"
    }
  },
  {
    "ts": null,
    "headline": "Diffuse Large B-cell Lymphoma Market Research Report 2025-2035 | Personalized Medicine and Precision Treatment Trends in DLBCL",
    "summary": "The Diffuse Large B-cell Lymphoma (DLBCL) market is witnessing significant growth, driven by advancements in targeted immunotherapies like CAR-T cell therapy and bispecific antibodies. These therapies are transforming the treatment landscape for relapsed or refractory cases, offering personalized, effective solutions. Despite exciting trends in precision medicine, the market faces challenges such as high treatment costs, resistance issues, and side effects associated with CAR-T therapy. However,",
    "url": "https://finnhub.io/api/news?id=acb747de31084bf7e4395f2a15d793cf18a3f91e9f2633ce65957db4eb27788c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753351140,
      "headline": "Diffuse Large B-cell Lymphoma Market Research Report 2025-2035 | Personalized Medicine and Precision Treatment Trends in DLBCL",
      "id": 136066252,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The Diffuse Large B-cell Lymphoma (DLBCL) market is witnessing significant growth, driven by advancements in targeted immunotherapies like CAR-T cell therapy and bispecific antibodies. These therapies are transforming the treatment landscape for relapsed or refractory cases, offering personalized, effective solutions. Despite exciting trends in precision medicine, the market faces challenges such as high treatment costs, resistance issues, and side effects associated with CAR-T therapy. However,",
      "url": "https://finnhub.io/api/news?id=acb747de31084bf7e4395f2a15d793cf18a3f91e9f2633ce65957db4eb27788c"
    }
  },
  {
    "ts": null,
    "headline": "Janssen’s Darzalex new indication gains EC approval for SMM",
    "summary": "Daratumumab is co-formulated with Halozyme's Enhanze technology.",
    "url": "https://finnhub.io/api/news?id=0f4c04230656130fde24fc969ffd0395d0a90ce9b769bf6e87b716c5be9b1819",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753350379,
      "headline": "Janssen’s Darzalex new indication gains EC approval for SMM",
      "id": 136066253,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Daratumumab is co-formulated with Halozyme's Enhanze technology.",
      "url": "https://finnhub.io/api/news?id=0f4c04230656130fde24fc969ffd0395d0a90ce9b769bf6e87b716c5be9b1819"
    }
  },
  {
    "ts": null,
    "headline": "Looking Beyond Yield for the Safest Dividend Payers",
    "summary": "Wolfe Research screened companies for dividend growth and stable free-cash-flow yield. Here are six names that made the list.",
    "url": "https://finnhub.io/api/news?id=9220f04895af709c68301bdc291a43696c191f3d5482ff18833dc260d53a6d6f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753342200,
      "headline": "Looking Beyond Yield for the Safest Dividend Payers",
      "id": 136066254,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Wolfe Research screened companies for dividend growth and stable free-cash-flow yield. Here are six names that made the list.",
      "url": "https://finnhub.io/api/news?id=9220f04895af709c68301bdc291a43696c191f3d5482ff18833dc260d53a6d6f"
    }
  },
  {
    "ts": null,
    "headline": "Mountain Valley MD Holdings Announces Changes to Board of Directors",
    "summary": "TORONTO, July 24, 2025--Mountain Valley MD Holdings Inc. (the \"Company\" or \"MVMD\") (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) is pleased to announce the appointment of David Batchelor to its board of directors.",
    "url": "https://finnhub.io/api/news?id=cfb25da818460eeeb06d794a1d0037c2c9d627621e03f3378cc9c135e1651755",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753321740,
      "headline": "Mountain Valley MD Holdings Announces Changes to Board of Directors",
      "id": 136062145,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "TORONTO, July 24, 2025--Mountain Valley MD Holdings Inc. (the \"Company\" or \"MVMD\") (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) is pleased to announce the appointment of David Batchelor to its board of directors.",
      "url": "https://finnhub.io/api/news?id=cfb25da818460eeeb06d794a1d0037c2c9d627621e03f3378cc9c135e1651755"
    }
  }
]